Additionally, 8 non-FCVs (67%) and 7 FCVs (70%) provide sulphonylureas, and 10 non-FCVs (83%) and 7 FCVs (70%) offer ACE inhibitors for diabetes and hypertension treatment. This evidence concerns the gene ACE and hypertensive disorder.